Venus Remedies’ record is a study in contradiction: five years of unqualified audit opinions and a declared zero-debt balance sheet sit alongside a US$4.59 million FCCB liability that has been unresolved since 2015. The company reports improving receivables, but the mechanics of a ₹38.68 crore write-off and a shifting offshore subsidiary structure demand a close look at what sits behind the reported numbers.
Key findings
- A time-barred FCCB liability of ₹38.68 crore was written off, splitting the gain between reserves and profit
Major- The Board wrote off a US$4.59 million FCCB liability in FY2024-25, routing ₹28.77 crore of principal to Capital Reserve and recognising ₹9.91 crore of unpaid interest as an exceptional item in the profit and loss statement. The bonds matured on 1 February 2015, and the company had not reinstated the carrying value at current exchange rates nor provided for interest since that date, based on a legal opinion that the liability was time-barred. In FY2019-20, the auditor issued multiple Emphasis of Matter paragraphs on various non-compliances, stating the financial impact was not ascertainable. - The company claims zero debt, but a US$4.59 million FCCB liability remains unresolved
Major- Venus Remedies reported “zero debt on the balance sheet” for FY26, its third consecutive year of zero debt. Yet FCCB bonds of US$4.59 million matured on 1 February 2015 remain unresolved, with the company treating the liability as time-barred under a legal opinion and making no interest provision since that date. The Board’s Report for FY21 stated there was no requirement to file a one-time settlement with any bank or financial institution, while the company disclosed one-time settlements for NPA loan accounts during the nine months ended 31 December 2020. - Audit opinions have been clean since FY2022, but a dense list of past non-compliance and a recurring FCCB emphasis of matter persisted for years
Major- The statutory auditor issued an unqualified opinion for FY2025-26. The FY2019-20 report, however, carried multiple Emphasis of Matter paragraphs citing non-compliance with Ind AS 109, Ind AS 19, Ind AS 36, Ind AS 115, and numerous other standards, with the financial impact stated as not ascertainable in each case. An Emphasis of Matter on the time-barred FCCB bonds appeared in the auditor’s reports for FY2021-22, FY2022-23, and FY2023-24, then described the write-off of the liability in the FY2024-25 reports. - An offshore subsidiary structure has been marked by negative net worth and a ₹28.6 crore share application pending for years
Major- The group structure stabilised around one wholly owned foreign subsidiary, Venus Pharma GmbH (Germany), from FY2021-22 onward. The auditor noted Venus Pharma GmbH’s net worth had turned negative by ₹1.32 crore as at 30 September 2025, and later highlighted it was negative by ₹94.15 lakhs as of 29 January 2026. Outstanding share application money of ₹28.6 crore in respect of Venus Pharma GmbH remained pending for allotment as of 29 January 2026, with the auditor noting allotment is not mandatory under German law. - A family-controlled board with guaranteed minimum remuneration has escalated managerial pay and seeks to add a second-generation director
Minor- The board has five inter-se family relationships: Mr. Pawan Chaudhary and Dr. Manu Chaudhary are married, Mr. Akshansh Chaudhary is their son, and Mr. Peeyush Jain and Mr. Ashutosh Jain are brothers of Dr. Manu Chaudhary. In FY2021-22, the average increase in managerial remuneration was 57.53% compared to an 18.15% average increase for all other employees. Mr. Saransh Chaudhary, son of Pawan and Manu Chaudhary, was appointed as Whole-Time Director for 5 years from 26 May 2026 at a salary of ₹93.00 Lacs per annum, with minimum remuneration guaranteed in case of loss. - The company states no impairment is required but does not disclose the assumptions behind that conclusion
Minor- In FY2019-20, the auditor issued an Emphasis of Matter stating Venus Remedies had not complied with Ind AS 36 requirements for impairment testing of goodwill and intangible assets, with the impact not quantifiable. From FY2021-22 through FY2025-26, the annual reports state that a review was undertaken and no provision for impairment was required, but none disclose the carrying amount of goodwill, the CGU allocation, or the key assumptions used for impairment testing. - Revenue quality is supported by a diversified international base and improving receivables
Clean- International business contributed 77% of total revenue in FY26 (₹590+ crore), up from 72% (₹468 crore) in FY25, with no single international market accounting for more than 10% of revenue. Trade receivables fell in absolute terms from ₹112 crore to ₹103 crore in FY26 despite revenue growth of 17.9%. The auditor issued an Emphasis of Matter in FY20 on non-compliance with Ind AS 115 revenue recognition, with the impact not ascertainable, but this has not recurred.
What to watch
- Venus Pharma GmbH restructuring. Management has engaged a Germany-based financial consultancy firm to advise on restructuring European operations as of 20 July 2026, with the ₹28.6 crore share application money still pending allotment.
- FCCB resolution. The board decided on 31 May 2021 to seek further course of action from the Reserve Bank of India regarding the US$4.59 million FCCB bonds; no update has been disclosed since.
- AGM vote on promoter remuneration. The 37th AGM, convened by notice dated 24 July 2026, will vote on the appointment of Mr. Saransh Chaudhary as Whole-Time Director and the reappointment of Dr. Manu Chaudhary at ₹153.50 Lacs per annum.
- Income tax refund litigation. The balance refund for AY 2011-12 and AY 2012-13 remains under litigation as disclosed in the FY2025-26 Annual Report.
Bottom line: This is a disclosed record with improving operating metrics and a regulatory history that includes multiple past non-compliances and a recurring FCCB emphasis of matter for years. The weight sits in two places: a US$4.59 million FCCB liability that has been unresolved since 2015, and a subsidiary structure where ₹28.6 crore of share application money sits unallotted against an entity with negative net worth. Read the zero-debt claim with the FCCB in mind, and watch whether the European restructuring gives the subsidiary a clear shape.